首页> 美国卫生研究院文献>Drug Target Insights >Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília Brazil During 2002–2008
【2h】

Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília Brazil During 2002–2008

机译:2002-2008年巴西巴西利亚采用高效抗逆转录病毒疗法治疗的艾滋病毒/艾滋病患者病毒学衰竭的预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to improve HIV/AIDS patients’ therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to unresponsiveness to the lentiviral treatment were: patients’ place of origin (OR = 3.28; IC95% = 1.0–9.73; P = 0.032) and Mycobacterium tuberculosis infection (RR = 2.90; IC95% = 1.19–7.02; P = 0.019). In the logistic regression analysis, the remaining variables in the model were: patients’ birthplace (OR = 3.28; IC95% = 1.10–9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; IC95% = 1.19–12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period of one year of treatment, predicting that T CD4+ low values and elevated viral loads at pretreatment should be particularly considered in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and immunological reconstitution.
机译:在巴西联邦区,关于抗逆转录病毒疗法疗效的数据很少,因此,为了改进艾滋病毒/艾滋病患者的治疗方法并查明治疗中的热点,进行了这项研究工作。在接受高活性抗逆转录病毒治疗的139名HIV / AIDS患者中,有12.2%的病毒学检查无效。与对慢病毒治疗无反应性相关的重要相关因素包括:患者的出生地(OR = 3.28; IC95%= 1.0-9.73; P = 0.032)和结核分枝杆菌感染(RR = 2.90; IC95%= 1.19-7.02; P = 0.019)。在Logistic回归分析中,模型中的其余变量为:患者的出生地(OR = 3.28; IC95%= 1.10–9.73; P = 0.032)和结核合并症(OR = 3.82; IC95%= 1.19–12.22; P = 0.024)。参与该调查的患者在一年的最大治疗期间内的治疗成功率为88.0%,预示在结核病合并感染中应特别考虑T CD4 + 的低值和治疗前病毒载量的升高,除了可获得在病毒抑制和免疫重建中均显示最佳活性的新型抗逆转录病毒药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号